Type II
interleukin-1 receptor (IL-1R2) is a non-signaling decoy receptor that negatively regulates the activity of
interleukin-1 (IL-1), a pro-inflammatory
cytokine involved in
atherogenesis. In this article we assessed the relevance of IL-1R2 in
atherosclerosis by studying its expression in monocytes from hyperlipidemic patients, in THP-1 macrophages exposed to
lipoproteins and in human atherosclerotic lesions. Our results showed that the
mRNA and
protein expression of IL-1R2 was reduced in monocytes from patients with
familial combined hyperlipidemia (-30%, p<0.05). THP-1 macrophages incubated with increasing concentrations of acetylated low density (ac-
LDL) and very low density (
VLDL) lipoproteins also exhibit a decrease in IL-1R2
mRNA and
protein levels. Pre-incubation with agents that block intracellular accumulation of
lipids prevents the decrease in IL-1R2
mRNA caused by
lipoproteins.
Lipoproteins also prevented the increase in IL-1R1 and IL-1R2 caused by a 4-h stimulation with LPS and reduced
protein expression of total and phosphorylated
IL-1 receptor-associated kinase-1. Finally, IL-1R2 expression in human atherosclerotic vessels was markedly lower than in non-atherosclerotic arteries (-80%, p<0.0005). Overall, our results suggest that under atherogenic conditions, there is a decrease in IL-1R2 expression in monocytes/macrophages and in the vascular wall that may facilitate
IL-1 signaling.